These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 29355950

  • 1. Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats.
    Nishi T, Yamamoto Y, Yamagishi N, Iguchi M, Tamai H, Ito T, Tsuruo Y, Ichinose M, Kitano M, Ueyama T.
    J Pharm Pharmacol; 2018 Mar; 70(3):383-392. PubMed ID: 29355950
    [Abstract] [Full Text] [Related]

  • 2. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
    Chong LW, Hsu YC, Lee TF, Lin Y, Chiu YT, Yang KC, Wu JC, Huang YT.
    BMC Gastroenterol; 2015 Feb 15; 15():22. PubMed ID: 25886887
    [Abstract] [Full Text] [Related]

  • 3. Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.
    Nakanishi K, Kaji K, Kitade M, Kubo T, Furukawa M, Saikawa S, Shimozato N, Sato S, Seki K, Kawaratani H, Moriya K, Namisaki T, Yoshiji H.
    Int J Mol Sci; 2019 Jun 03; 20(11):. PubMed ID: 31163617
    [Abstract] [Full Text] [Related]

  • 4. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y, Kurosaki E, Takasu T, Mitori H, Yamazaki S, Koide K, Takakura S.
    Eur J Pharmacol; 2015 May 05; 754():19-24. PubMed ID: 25701721
    [Abstract] [Full Text] [Related]

  • 5. Deletion of nardilysin prevents the development of steatohepatitis and liver fibrotic changes.
    Ishizu-Higashi S, Seno H, Nishi E, Matsumoto Y, Ikuta K, Tsuda M, Kimura Y, Takada Y, Kimura Y, Nakanishi Y, Kanda K, Komekado H, Chiba T.
    PLoS One; 2014 May 05; 9(5):e98017. PubMed ID: 24849253
    [Abstract] [Full Text] [Related]

  • 6. Antihypertensive therapy improves insulin resistance and serum levels of interleukin-6 and -10 in spontaneously hypertensive rats with steatohepatitis.
    Kozono M, Uto H, Ibusuki R, Arima S, Oda K, Taguchi H, Sasaki F, Nasu Y, Hashimoto S, Setoyama H, Kanmura S, Numata M, Tsubouchi H, Ido A.
    Mol Med Rep; 2016 Dec 05; 14(6):5385-5394. PubMed ID: 27779710
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model.
    Shimozono R, Asaoka Y, Yoshizawa Y, Aoki T, Noda H, Yamada M, Kaino M, Mochizuki H.
    Mol Pharmacol; 2013 Jul 05; 84(1):62-70. PubMed ID: 23592516
    [Abstract] [Full Text] [Related]

  • 9. Combination of Hypertension Along with a High Fat and Cholesterol Diet Induces Severe Hepatic Inflammation in Rats via a Signaling Network Comprising NF-κB, MAPK, and Nrf2 Pathways.
    Yuan Y, Naito H, Jia X, Kitamori K, Nakajima T.
    Nutrients; 2017 Sep 14; 9(9):. PubMed ID: 28906458
    [Abstract] [Full Text] [Related]

  • 10. Aloin protects mice from diet-induced non-alcoholic steatohepatitis via activation of Nrf2/HO-1 signaling.
    Xu Q, Fan Y, Loor JJ, Liang Y, Lv H, Sun X, Jia H, Xu C.
    Food Funct; 2021 Jan 21; 12(2):696-705. PubMed ID: 33410857
    [Abstract] [Full Text] [Related]

  • 11. Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model.
    Aoyama Y, Naiki-Ito A, Xiaochen K, Komura M, Kato H, Nagayasu Y, Inaguma S, Tsuda H, Tomita M, Matsuo Y, Takiguchi S, Takahashi S.
    Nutrients; 2021 Dec 23; 14(1):. PubMed ID: 35010924
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.
    Douhara A, Moriya K, Yoshiji H, Noguchi R, Namisaki T, Kitade M, Kaji K, Aihara Y, Nishimura N, Takeda K, Okura Y, Kawaratani H, Fukui H.
    Mol Med Rep; 2015 Mar 23; 11(3):1693-700. PubMed ID: 25421042
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.
    Simon Y, Kessler SM, Gemperlein K, Bohle RM, Müller R, Haybaeck J, Kiemer AK.
    World J Gastroenterol; 2014 Dec 21; 20(47):17839-50. PubMed ID: 25548482
    [Abstract] [Full Text] [Related]

  • 17. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K, Szabo G.
    J Transl Med; 2015 Jun 16; 13():193. PubMed ID: 26077675
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease.
    Takeuchi-Yorimoto A, Yamaura Y, Kanki M, Ide T, Nakata A, Noto T, Matsumoto M.
    Toxicol Lett; 2016 Sep 06; 258():159-167. PubMed ID: 27320964
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.